問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


China Medical University Hospital (在職)

Division of Pediatrics

更新時間：2023-09-19

王仲興Wang, Chung-Hsing
  • Principal Investigator
  • Clinical Trial Experience (year) 13 years 1 個月

Recruiting Trial

2Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

王仲興

List

9Cases

2017-04-01 - 2019-12-31

Phase III

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Recruiting2Sites

Terminated2Sites

牛道明
Taipei Veterans General Hospital

Division of Pediatrics

2023-01-01 - 2025-10-31

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Recruiting1Sites

Terminated4Sites

2026-10-31 - 2030-07-30

Phase III

Not yet recruiting

  • Condition/Disease

  • Test Drug

Participate Sites
2Sites

Not yet recruiting2Sites

2024-05-01 - 2028-12-31

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Recruiting4Sites

2026-07-14 - 2029-12-31

Phase III

Not yet recruiting

  • Condition/Disease

  • Test Drug

Participate Sites
2Sites

Not yet recruiting2Sites

2024-01-01 - 2025-12-31

Phase IV

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
11Sites

Terminated11Sites

2012-06-01 - 2018-11-30

Phase III

Not yet recruiting

  • Condition/Disease

  • Test Drug

Participate Sites
2Sites

Terminated2Sites

2017-12-08 - 2023-02-01

Phase III

A 26 Week, Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel Group, Phase 3 Trial With a 26 Week Safety Extension Period Evaluating the Safety and Efficacy of Dapagliflozin 5 and 10 mg, and Saxagliptin 2.5 and 5 mg in Pediatric Patients With Type 2 Diabetes Mellitus Who Are Between 10 and Below 18 Years of Age

  • Condition/Disease

    Type 2 Diabetes Mellitus in Pediatric Patients

  • Test Drug

    Dapagliflozin / Saxagliptin

Participate Sites
3Sites

Recruiting2Sites

Suspended1Sites

牛道明
Taipei Veterans General Hospital

2017-08-01 - 2020-05-31

Phase III

Prospective, Randomized, Double-Blind Comparison of LY900014 to Insulin Lispro with an Open-Label Postprandial LY900014 Treatment Group, in Combination with Insulin Glargine or Insulin Degludec, in Adults with Type 1 Diabetes PRONTO-T1D.

  • Condition/Disease

    Type 1 Diabetes Mellitus

  • Test Drug

    LY900014

Participate Sites
6Sites

Terminated6Sites

歐弘毅
National Taiwan University Hospital

Division of Endocrinology

聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB